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1. SUMMARY 
Women in Africa are disproportionately affected by human immunodeficiency virus type 1 
(HIV-1) and many are unable or unwilling to negotiate condom use due to cultural/traditional 
behaviour or simply wants to conceive. For that reason, the development of a drug delivery 
system loaded with vaginal microbicide would be of greater benefit to inhibit the spread of HIV-1 
not only in disadvantaged areas, like Africa, but also at global scale. 
In this study, different formulations containing a fusion inhibitor peptide as a microbicide 
have been prepared. These two preparations consist of two nanosystems, poly(lactic-co-glycolid 
acid (PLGA) coated with polyvinyl alcohol (PVA) nanoparticles (NPs) and 1-Palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC) large unillamelar vesicles (LUVs), that improve tissue 
absorption, penetration and targeting for peptide anti-HIV-1 activity. 
PLGA-PVA NPs were formulated via solvent displacement and POPC LUVs via the 
hydration of thin film method, both formulations loaded with the peptide. Size, polidispersion 
index (PdI), zeta potential (Zpot) and entrapment efficiency (EE) were determined to evaluate 
their properties. It was necessary to evaluate the stability of the liposomes and nanoparticles at 
4 ° C by measuring their size and polydispersity over a period of one month and a half.  
Both formulations were characterized to determine peptide release rate using a synthetic 
membrane (in vitro study) and vaginal mucosa permeation (ex vivo study). Previously studies 
had assayed the stability of the peptide using the same conditions.  
Keywords: HIV-1, microbicides, drug delivery system, liposome, nanoparticle, fusion inhibitor 
peptide, vaginal mucosa. 
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2. RESUM 
A l’Àfrica, el nombre de dones afectades pel virus de la immunodeficiència humana del 
tipus 1 (HIV-1) és molt superior al nombre d’homes. Les dones, per diversos motius, es veuen 
amb la impossibilitat de fer us dels preservatius. Així que, el desenvolupament d'un sistema 
d'administració que incorpori un microbicida vaginal seria molt beneficiós per inhibir la 
propagació del VIH-1, no només per zones desfavorides com l’Àfrica, sinó també a nivell 
mundial.  
En aquest estudi, s'han preparat diverses formulacions que contenen un pèptid inhibidor de 
la fusió cel·lular que actua com a microbicida. Aquestes dues preparacions consisteixen en dos 
nanosistemes, el primer format per nanopartícules (NPs) de poli (àcid làctic-co-glicólido (PLGA) 
recobertes amb alcohol de polivinil (PVA), i el segon consisteix en liposomes de 1-palmitoil-2-
oleoil-sn-glicero-3-fosfocolina (POPC). Aquest sistemes milloren l'absorció als teixits, la 
permeació i l'orientació del pèptid amb activitat anti-HIV-1. 
Les NPs de PLGA-PVA es van preparar mitjançant el mètode de desplaçament de solvent i 
els liposomes de POPC,  mitjançant la resuspensió del lípid seguit de cicles de congelació i 
descongelació, formant  vesícules unil·lamelars grans (LUVs), ambdues formulacions 
carregades amb el pèptid. Per avaluar les seves propietats es va determinar la mida de la 
partícula, l’índex de polidispersió (PdI), el potencial zeta (Zpot) i l'eficàcia d’encapsulació (EE). 
Per determinar l’estabilitat de les formulacions va ser necessari mesurar la mida de partícula i el 
PdI a 4 °C durant un mes i mig. 
Els dos nanosistemes i el pèptid lliure es van avaluar mitjançant estudis in vitro i ex vivo per 
determinar la velocitat d'alliberament del pèptid  en una membrana sintètica i la seva permeació 
en la mucosa vaginal. Per altra banda, es va realitzar l'estabilitat del pèptid usant les mateixes 
condicions. 
Paraules clau: HIV-1, microbicides, Sistema d’administració de fàrmacs, liposoma, 
nanopartícula, pèptid inhibidor de la fusió, mucosa vaginal.
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3. INTRODUCTION 
Cure and prevention of human immunodeficiency virus infection (HIV) pandemic has been a 
major challenge for the scientific community for the last thirty years. Women in the world are 
notably more vulnerable to HIV than men. This fact is supported by several studies in developed 
countries, which prove that women up to 24 years old are HIV-positives by 4:1 compared 
against men in the same range of age [1]. In 2015, there were more than 2.1 million of new HIV 
infections around the world. However, these new infections were mainly based in Africa and 
most of them were young women [2].  
Most experts indicate that “treatment as prevention” is an important approach to eradicate 
the HIV epidemic around the world. The main method of prevention in most of the countries of 
the world is the use of condoms. The use of condoms must be agreed by both and 
unfortunately, in most of the countries, due to the different cultures or religions, it always 
depends on men. For that reason, women are unprotected against possible infections. At the 
same time, condoms are the main contraceptive, so they cannot be used by women who want 
to conceive, increasing the risk of HIV. Not only the cultural or the religion issue affects the use 
of the condoms, in the poorest regions of the world, the use of the condoms is dramatically 
reduced because of their cost, forcing the people to have unprotected sex. 
Regarding prevention is one of the most common recommendations to reduce the HIV 
epidemic, multiple approaches are required to mitigate the growth of infections and the 
microbicides have been approved as suitable solution for it. Microbicides have an 
unprecedented potential for mitigating the global burden from HIV infection by heterosexual 
contact. In the present study, different formulations of anti-HIV vaginal delivery systems that act 
as microbicide have been developed, being one of the best alternatives for women to be able to 
protect themselves. 
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3.1.  HUMAN IMMUNODEFIENCY VIRUS (HIV)  
The HIV is the infectious agent that causes acquired immune deficiency syndrome (AIDS). 
The virus causes the disease by attacking CD4+ lymphocytes destroying the immune system.  
There are two types of HIV: HIV-1 and HIV-2. HIV-1 is more common, virulent and infective 
than HIV-2. The way HIV-1 HIV infects is through direct contact with certain body fluids such as 
blood, semen and pre-seminal fluid, vaginal fluids, rectal fluids and breast milk. 
HIV-1 is an RNA virus of the Retroviridae family and belongs to the Lentivirus genus. HIV-1 
(figure 1) is composed of a lipid membrane in which glycoproteins 120 and 41 (gp120 and gp41 
are inserted. Inside the viral capsid two copies of RNA are located and stabilized by protein 
complexes which include the nucleocapsid protein p7 (NU). In the interior of the capside there 
are found the enzymes required by the viral replication (reverse transcriptase (TI), protease 
(PR) and integrase (IN)), as well as regulatory proteins. 
 
 
 
 
 
 
 
Figure 1. HIV-1 virion. (Figure reproduced from US National Institute of Health). 
The binding and fusion of HIV-1 to the cell, as shown in figure 2, is given by the interaction 
of glycoprotein 120 (gp120) with receptor CD4+ of the host cell. This binding triggers a 
conformational change in the gp120/CD4+ complex, leading to the interaction of gp120 with the 
coreceptors CCR5 and CXCR4. Then, another conformational change occurs, but this time in 
gp41. The hydrophobic sequence of amino acids on the N-terminus of gp41, which is also 
known as fusion peptide (FP), generates the union and fusion of the membranes of the virion 
and the host cell [3] 
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Figure 2. Interactions of HIV-1 envelope proteins with cellular membrane lipids during target cell binding 
(A) and fusion steps (B). (Figure reproduced from Ref 3). 
3.2.  VAGINAL TRANSMISSION OF HIV 
To try to develop a possible microbicide, it is important to understand the stages involving 
transmission of HIV through the vaginal mucosa surface (figure 3). 
HIV present in semen or by donor HIV-infected leukocytes requires to firstly cross mucus 
fluids covering the mucosa. Then, virus can enter through the stratified vaginal epithelium by 
different pathways. One is by direct access to the lamina propria across gaps in the epithelium 
(a). Another mechanism involves Langerhans cells (LCs): these cells are a type of dendritic 
cells present in the mucosa that trap the virus and transport it through the epithelium (b). It may 
be the case that some of intraepithelial CD4+ T cells (or other leukocytes) infected by virus 
penetrate lamina propria (c). In the last case, by transcytosis of virions across the epithelial cell 
line barrier (d). Once the HIV has passed through the epithelium it can infect the target cells (e), 
which are CD4+ T lymphocytes, CD4+ cells of the macrophage lineage and the Dendritic cells 
(DCs). Eventually, free virus (f), infected cells (g) or non-productively infected DCs (h) are 
transferred to lymph nodes, where it will stablish a systemic infection (f). To try to develop a 
possible microbicide, it is important to understand the stages involving transmission of HIV 
through the vaginal mucosa surface [4]. 
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Figure 3. Mechanisms of transmission of cell-free HIV through the vaginal mucosa. (Figure reproduced 
from Ref 4). 
3.3 MICROBICIDE, ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)  
Microbicides are novel topical products containing APIs to block the infection by pathogens. 
These APIs may be released intravaginally, using different delivery systems as gels, tablets, 
suppositories, emulsion type formulations and microparticulate or nanoparticulate systems [5]. 
Microbicides are classified in two types: physical barriers (physically blocking virus entry) 
and chemical barriers (APIs). Chemical barrier microbicides block HIV replication before the 
integration of the virus into the host cells.  Numerous classes of APIs have been tested as 
vaginal microbicides, including virucidal agents (detergents), CCR5 co-receptor antagonist, 
lectins and neutralizing monoclonal antibodies, entry/fusion inhibitors, nucleoside reverse 
transcriptase inhibitors (NRTIs) or non-nucleosides reverse transcriptase inhibitors (NNRTIs), as 
Tenofovir (TFV), Dapivirine (DPV), and the viral integrase inhibitors [5].  
There are various types of microbicides which have been developed in pre-clinical and 
clinical studies. The first break-through in the field of microbicidal research was the outcome of 
the CAPRISA 004 (Centre for the AIDS Program of Research in South Africa) trial, using a 1% 
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vaginal Tenofovir gel which reduced the transmission of HIV by 39%. However, the VOICE 
(Vaginal and Oral Interventions to Control the Epidemic) study halted the oral Tenofovir and 
Tenofovir gel, because data analysis showed that the results were not so promising [5]. 
This study is focused on peptides microbicides that inhibit the entry of HIV-1 into the host 
cells. These compounds have been shown to be successful in the inhibition of early events of 
the infection, so they have benefits in front of microbicides such as Tenofovir or Dapivirine due 
to peptides are able to target the HIV-1 in the lumen of the vagina, before genital tissue 
penetration and dissemination towards the lymph nodes [5]. In the literature, several peptides 
have been reported as fusion inhibitors of gp41 (T20, T1249, C34, L’644 and Sifuvirtide): they 
have been pre-clinically evaluated as putative microbicides. Fusion inhibitors targets different 
domains of the gp41 blocking the formation of the post fusion hairpin state [6].  
Our microbicide candidate is a fusion inhibitor peptide named E1P47, that can act as 
preventive or therapeutic drug due the fact it can act before the virus enters into target cells.  
This synthetic peptide is an 18-mer that comes from the GB virus C (GBV-C) E1 protein. 
GBV-C is a non-pathogenic virus that is usual in HIV infected individual due to its transmission 
through the same routes. The studies carried out in 1998 discovered the patients co-infected 
with GBV-C and HIV had an unexpected benefit [7]. Co-infected patients showed a lower 
progression of the disease and a higher survival once AIDS had already been developed [8].     
E1P47 has a high anti-HIV activity because it interacts with the fusion peptide (figure 4), and 
this is essential for viral entry and it does not allow the union and fusion of the membranes of 
the virion and the host cell [9].  
 
Figure 4. Schematic mechanism of a GBV-inhibitor peptide (E1P47) with fusion peptide (Figure 
reproduced from Ref 9.) 
 
E1P47 
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3.4  NANOCARRIERS FOR VAGINAL DRUG DELIVERY AND STUDIES ON DRUG DELIVERY 
PERMEATION  
Developing an active microbicide product not only requires a potent anti-HIV drug 
compound, but also a suitable formulation strategy which will affect both safety and bioavaility. 
There are proved several vaginal drug delivery systems such as gels, tablets, 
suppositories/pessaries, emulsion-type formulation, microparticulate systems and 
nanoparticulate systems have been good candidates [5]. 
Nanosystems are defined as vehicles with particles size 10-300 nm, which compounds can 
be dissolved in, encapsulated in, or attached to for delivery [4]. The advantages of using 
nanocarriers in microbicides are related mostly with the protection provided to active agents 
(when they are entrapped in the nanosystem) and to the capability of nanocarriers to facilitate 
APIs to approach the target cells in the vaginal. Carriers are particularly attractive since they 
provide protection to the drug, increase drug efficacy, permeate physiological barriers and 
decrease toxicity [4]. 
In this study two nanosystem formulations have been assayed, nanoparticles (NPs) and 
liposomes.  
First one, NPs (figure 5), are defined as particulate dispersions. The drug is dissolved, 
entrapped, encapsulated or attached to a nanoparticle matrix. Depending upon the method of 
preparation, nanoparticles, nanospheres or nanocapsules can be obtained. Nanocapsules are 
systems in which the drug is confined to a cavity surrounded by a unique polymer membrane, 
while nanospheres are matrix systems in which the drug is physically and uniformly dispersed.  
In this study, the nanoparticle formation method was solvent displacement due the hydrophobic 
character of our peptide [10]. Solvent displacement is a method that allows obtaining 
nanospheres [5].  
Figure 5. A schematic illustration of (a) nanosphere and (b) nanocapsule. (Figure reproduced from Ref 
10). 
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Controlled release and particle degradation characteristics can be readily modulated by the 
choice of matrix constituents. For our experiments poly(lactic-co-glycolid acid) (PLGA) have 
been chosen because of their biodegradability and biocompatibility and has been approved by 
U.S Food and Drug Administration (FDA). PLGA copolymers are widely investigated for the 
vaginal controlled release because their mucoadhesive properties. 
Liposomes (figure 6) are the second nanocarrier formulation, lipid-based drug delivery 
system are usually composed of polar lipids such as phospholipids, triglycerides and fatty acids 
which are biocompatible and biodegradable, making them ideal drug delivery vehicles. 
Liposomes are concentric bilayered vesicles in which an aqueous volume, containing the 
peptide drug, is entirely enclosed by a membranous lipid bilayer. They can be classified 
according to their size and lamellar forms. Figure 6 shows various forms of lamellar and sizes 
[10]. 
Figure 6. A schematic illustration of a liposome (a) various forms of lamellar and sizes; small 
unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs), giant unilamellar vesicles (GUVs), 
multilamellar and multivesicular. (Figure reproduced from Ref 10) 
The type of phospholipid used is 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). 
POPC has a phosphocholine (PC) head group. Since the lipid PC is the most abundant in the 
cellular membranes, this has been chosen so that the interaction with the target cells could be 
very strong.   
There are several methodologies that led researchers to characterize and predict drug 
permeation. In this studied, there are carried out two permeation tests. First of all, an in vitro 
study has been conducted to characterize the release of free drug and encapsulated drug in the 
two formulations using a synthetic, inert and highly permeable membrane. The second one, an 
ex vivo methodology has been used to predict drug permeation through the vaginal barrier using 
vaginal tissue. Franz cells are used as a permeation system to carry out the two experiments. 
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This model constitutes the methodology of reference in The United States Pharmacopeia (USP) 
for drugs products that institution defines the performance tests for vaginal administration, which 
are focused on the assessment of in vitro drug release [11]. 
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4. OBJECTIVES 
The main objective of this work is the design of delivery systems of an HIV-1 entry inhibitor 
as a microbicide and to study peptide permeation on porcine vaginal mucosa. To attain this 
general objective, the specific ones are: 
- Preparation and characterization of the two formulations: nanoparticles (NPs) and 
liposomes loaded with E1P47 peptide. 
- Study of stability of both nanosystems at 4ºC. 
- Study of stability of E1P47 at 37ºC. 
- In vitro and ex vivo assays to study the release and permeation of two 
formulations and free peptide. 
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5. EXPERIMENTAL SECTION 
5.1 REAGENTS AND SOLVENTS   
Preparations of LUVs 
Entry Supplier Reagents 
1 Avanti Polar Lipids POPC 
2 Merck Chloroform, methanol, 
KH2PO4, Na2HPO4, KCl 
3 Sigma-Aldrich DMSO 
4 Mill-Q H2O 
5 Carlo Erbo NaCl 
 
Preparation of NPs 
Entry Supplier Reagents 
1 BASF PVA 
2 Aldrich PLGA Mw: 7000-17000 
3 Mill-Q H2O 
4 Carlo Erbo Acetona, NaCl 
 
In vitro and ex vivo studies 
Entry Supplier Reagents 
1 Gattefossé Transcutol 
2 Fischer ACN 
3 Mill-Q H2O 
4 Carlo Erbo Acetone 
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5.2 INSTRUMENTATION 
 
Entry Supplier Instrument 
1 Agilent 1260 Infinity HPLC 
2 Agilent Column HPLC C18 
3.5 µm, 4.6 x 100 mm 
3 Gilson Pipetes 
4 Heidolph Rotavapor 
5 Lipex TM Extruder Extruder 
6 AQQUITY WATERS UPLC-MS/MS 
7 Agilent Column UPLC Zorbax C8 
1.8 μm, 2.1 mm × 50 mm 
8 Milipore Milli Q water equip 
9 Metller Toledo Balance 
10 Selecta Water Bath 
11 Selecta Ultrasonic Bath 
12 Lioalfa, Telstar Lyophilazer 
13 Lipex TM Extruder Extruder 
14 Whatman Polycarbonate filters 
(200nm and 100nm) 
16 Medicell membranes LTD Synthetic Membrane   
(3500 Da) 
17 Z sizer Nano ZS, Malvern 
instruments 
Zetasizer 
18 Beckman Ultracentrifuge 
19 Amicon Ultra Centrifugal filters 0.5 mL 
(3K) 
20 Eppendorf Centrifuge 
21 Hanson Research Cell Manual diffusion test 
system 
22 Vidra Foc Franz cell 
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5.3 PREPARATION OF FORMULATIONS   
To perform the release and permeation studies two different formulations were chosen, 
PLGA-PVA NPs and POPC LUVs, both loaded with E1P47.  E1P47 was synthesized manually 
in the solid phase following the Fmoc/tBu protection strategy in the Unit of Synthesis and 
Biomedical Applications of peptides (IQAC-CSIC). Crude peptides extracts were purified using 
semipreparative HPLC to >95% purity.  
5.3.1. Preparation LUVs with E1P47  
LUVs of POPC containing E1P47 were prepared at 4 mM concentration. POPC was 
dissolved in 1 mL of chloroform/methanol 2:1 (v/v) mixt, after that the lipid solution was dried by 
evaporation under vacuum. A thin film was formed and finally the film was lyophilized overnight. 
The film was resuspended in PBS buffer with E1P47 at 0.5 mg/mL and 3% of DMSO. The 
mixture was sonicated until a film disappear obtaining a white suspension, formed by 
multilamellar vesicles (MLVs) and they were frozen and thawn ten times. After that step, freeze 
and thaw multilamellar vesicles (FTMLV) were obtained. To prepare LUVs, FTMLV was 
extruded (figure 7) in 2 times through 200nm and 5 times through 100 nm pore-size 
polycarbonate filters. In practice, blank liposomes were prepared by the method described 
previously. 
Figure 7. Extruder 
5.3.2. Preparation of NPs with E1P47  
PLGA-PVA NPs containing E1P47 peptide were prepared by the solvent displacement 
technic described [7] (figure 8). 24 mg of PLGA polymer and 2 mg of E1P47 peptide were 
weighed and then dissolved in 2 mL of acetone. The organic solution was poured into 6 mL of 
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aqueous solution containing 10 mg/mL of PVA under moderate magnetic stirring. PVA was used 
as a stabilizer to produce NPs. Acetone was evaporated under reduced pressure. The NPs 
were centrifuged at 14000 rpm at 4ºC 4 times for 45 minutes. Then, the NPs pellet was washed 
with deionized water. The final colloidal suspension was concentrated to the desired volume. 
Blank PLGA-PVA NPs were prepared by solvent displacement method described previously. 
Figure 8. Elaboration of nanoparticles by the method of displacement of the solvent (Figure 
reproduced from Ref 15). 
5.4. CHARACTERIZATION OF FORMULATIONS  
5.4.1. Particle size, zeta potential and polidispersity (PdI) 
Particle size, polydispersity and zeta potential were determined by dynamic light scattering 
using a Zetasizer nano ZS at 25ºC and scattering angle of 90º. In order to do the 
measurements, the samples were previously diluted 1:10 (v/v) in water. The assays were 
carried out in triplicate.  
5.4.2. Entrapment efficiency (EE) 
The amount of E1P47 entrapped in the NPs and liposomes was calculated by the difference 
between the total amount of peptide in the formulation and the amount of non-entrapped peptide 
remaining in the aqueous supernatant. The nanosystems were diluted 1:10 (v/v) in water, later 
was determined following the separation of free E1P47 from E1P47-loaded nanosystems by 
centrifugation of the suspensions in centrifugal device (3 kDa MWCO) at 12000 rpm for 30 min. 
The amount of free E1P47 in the supernatant was determined by high-performance liquid 
chromatography (HPLC) analysis at 220 nm using a C18 column, using linear gradient of 95% 
to 0% A in B over 20 minutes at flow rate 1 mL/min using 0.05% TFA in water (A) and 0.05% 
TFA in ACN (B) as the eluting system. E1P47 entrapment efficiency was calculated using the 
equation below (equation 1).  
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                                        Equation 1 
 
  5.4.3 Stability at 4ºC 
Particles were storage at 4ºC for 40 days to evaluate their stability, determining their size 
and PdI. 
5.5. STABILITY OF E1P47 
The stability of E1P47 was evaluated using an ultra-performance liquid chromatography-
tandem mass spectrometry (UPLC-MS/MS) method. A known concentration of E1P47 in 
transcutol ®/H2O 1:1 (v/v) was incubated at room temperature and 37ºC. A 100 µL aliquot was 
removed several times for 48 hours.  
5.6. IN VITRO RELEASE STUDY  
The release study was carried out for 2 days using Franz-type diffusion cells (figure 9) with 
dialysis cellulose membranes. This cell consists of two compartments, a donor compartment 
and a receptor compartment. The cellulose membrane is placed between de donor and the 
receptor compartments. The effective diffusional area was 0.632 cm2 and the receptor 
compartment capacity was 5 mL, which was filled with transcutol®/H2O 1:1 (v/v). In the donor 
compartment 0.4 mL of the formulations were placed in duplicated (E1P47 dissolved in 
transcutol®/H2O 1:1 (v/v), POPC LUVs E1P47 and PLGA-PVA E1P47). The system was kept at 
37ºC and stirred continuously at 700 rpm. Samples (0.3 mL) were withdrawn at selected time 
intervals and were replaced with the same volume of receptor medium. All samples were 
analysed by UPLC-MS/MS. 
Figure 9. Schematic representation of a Franz cell. (A) donor compartment; (B) membrane; (C) 
sampling port; (D) stirbar; (E) water outlet; (F) water inlet. (Figure reproduced from Ref 11). 
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To determine the peptide remaining in the cellulose membrane, E1P47 was extracted from 
the membrane with ACN/H2O 1:1 (v/v) medium for 30 minutes under sonication in an ultrasound 
bath. The supernatant was analysed by UPLC-MS/MS. 
5.7. EX VIVO PERMEATION STUDY  
The experiment was carried out under the protocol approved by the Animal Experimentation 
Ethics Committee of the University of Barcelona (Spain) and the Committee of Animal 
Experimentation of the regional autonomous of Catalonia (Spain). The vaginal mucosa was 
provided by the Animal Facility at Bellvitge Campus University (University of Barcelona, Spain). 
The study was carried out with fresh porcine vaginal mucosa from two animals. The fresh 
vaginal tissues were transported to the laboratory in containers filled with Hank’s solution.  
Each of the tissues was trimmed with surgical scissor in three adequate pieces. Then, the 
tissues were mounted on specially designed membrane holders with a permeation hold 
diameters of 1.2 cm which has a diffusion area of 0.632 cm2 (S).  For the permeation study, 
Franz -type diffusion cells were used. The membrane holder was mounted between the two 
compartments with the epithelium side facing the donor chamber and the connective tissue 
region facing the receptor chamber. Transcutol®/H2O 1:1 (v/v) was used in the receptor 
compartment. In the donor compartment 0.4 mL of the formulations were placed (E1P47 
dissolved in transcutol®/H2O 1:1 (v/v), POPCLUVs E1P47 and PLGA-PVA E1P47 NPs). 
Samples from both animals were used as replicates for each formulation. All over the process 
the receptor compartment was incubated at 37ºC to mimic in vivo mucosa by insulating jacket, 
the receptor phase was constantly stirred by magnetic stirrer at 700 rpm. At the predetermined 
time (1, 2, 3, 4, 5 and 6 hours), 0.3 mL of acceptor solution was removed via syringes from the 
centre of the cell and immediately replaced by the fresh receptor solution. The withdrawn 
supernatant was analysed to determine the content of E1P47 by UPLC-MS/MS. 
The tissues were frozen at 20ºC and the mucosa was trimmed by the contact area of donor 
compartment. The peptide retained at the vaginal mucosa was punctured. Then was extracted 
during 30 minutes under sonication in an ultrasound bath with 1 mL (VP) of ACN/H2O Milli Q 1:1 
(v/v) medium. The medium was retired from de mucosa (extracted mucosa concentration; Cp) 
and the vaginal mucosa was weighted (mucosa weight; Wp). The supernatant was analysed by 
UPLC-MS/MS. 
22 Paús Frutos, Anna 
 
To determine the recovery of E1P47 in mucosa 1.2 mL (V1) a solution of known (Co) of 
E1P47 in transcutol® /H2O 1:1 (v/v) was added to three previously weighted tissue sample (Wt). 
The samples were introduced into a 37 ° C bath for 6 hours, next the supernatant (non- 
permeabilized concentration; Ctrans) was separated from the tissue. The three tissues were 
weighted (Wt’). Then 1 mL (V2) of ACN/H2O 1:1 (v/v) was added. The vaginal mucosa samples 
were sonicated in ultrasound for 30 min finally the supernatant was removed from the tissue 
(Cacn), the resulting supernatant was measured by UPLC-MS/MS. 
To calculate the recovery percentage of the drug in the tissue applied the following equation 
2:  
            
         
   
(       )   
  
                                   Equation 2 
 
To determinate the real amount of peptide that was retained inside the mucosa was applied 
the following equation 3: 
                     
      
     
   
   
          
                              Equation 3 
5.8. QUANTIFICATION OF E1P47 BY UPLC-MS/MS 
All samples were analysed by UPLC-MS/MS. This system consisted of a triple quadrupole 
mass spectrometer (TQD) with an electrospray ionization (ESI) coupled to an UPLC. The 
autosampler was at room temperature during operation. The samples were analysed using a C8 
column, under a gradient elution at a flow rate of 0.30 mL/min. Mobile phase A consisted of 
ACN 0.1% acid formic (FA) and mobile phase B consisted of water 0.1% FA. The gradient was 
initiated at 5% A for 30 seconds and increased to 100% A in 8 min.  The capillary voltage (2.5 
kV), collision energy (15 V), cone gas flow (30 L/h), cone voltage (40 V), desolvation gas flow 
(800 L/h), and desolvation temperature (350 °C) were optimised for the multiple reaction 
monitoring (MRM) intensity of E1P47. 
5.8. DATA ANALYSIS 
The stability study of peptide was analysed using GraphPad Prism 5 program.  
The permeation parameters and the resultant of accumulative drug versus time for 
permeation studies were fitted by an appropriate model using the WinNonlin computer program 
(Pharsight 5.2, Mountain View, CA).  
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6. RESULTS AND DISCUSSION 
6.1 PHYSICOCHEMICAL STUDY PARAMETERS AND ENTRAPMENT EFFICIENCY 
NPs and liposomes are good candidates for their properties on vaginal delivery of 
microbicides. Mucins, through the establishment of intramolecular and intermolecular 
interactions, lead to the formation of an heterogeneous and intricate tridimensional aqueous 
channel network [12]. Particles might be retained along the network depending on their surface 
and size properties. 
PLGA and PVA polymers are good candidates to produce NPs for their functional 
properties, biological behaviour and their biocompatibility and biodegradability. Surface 
hydrophobicity conferred by PLGA polymer contributes to adhesion, as it promotes the 
establishment of bonding hydrophobic regions of mucin. PVA is also used as a surface stabilizer 
for PLGA NPs and its ability to impair particle migration through cervicovaginal mucus due to 
PVA surface adsortion has been demonstrated [12]. 
Liposomes of POPC have a lot of qualities due the fact they are composed by a synthetic 
phospholipid endowing them completely biocompatible, biodegradables, non-toxic and non-
immunogenic [1]. 
To understand the behaviour of our particles across the mucus, (mucoadhesion, drug 
release, drug loading and stability), it is necessary to characterize their physicochemical 
parameters such as particle size, PdI and zeta potential by dynamic light scattering technique. 
As shown in table 1, peptide entrapment or association to PLGA-PVA NPs influenced their 
size, which increased slightly due to the interaction of PLGA-PVA NPs surface with E1P47. 
LUVs E1P47 did not exhibit and important variation in in size whether they were loaded with 
E1P47 or not. Both formulations had PdI values lower than 0.1, indicating narrow particles size 
distribution. 
PLGA-PVA E1P47 NPs and POPC LUVs E1P47 tested in this study were smaller than 500 
nm (table 1), then both formulations can distribute in cervicovaginal mucosa suggesting that 
steric obstruction should be minimal [5, 12].  
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Formulation Size ± SD (nm) PdI ± SD 
PLGA-PVA NPs free 245 ± 2 0.094 ± 0.004 
PLGA-PVA-E1P47 NPs 240 ± 2 0.07 ± 0.05 
POPC LUVs free 242 ± 3 0.09 ± 0.01 
POPC LUVs E1P47 250 ± 10 0.11 ± 0.01 
Table 1. Size Distribution and PdI PLGA-PVA NPs, PLGA-PVA-E1P47 NPs and LUVs E1P47 (n=30). 
Zeta potential parameter is used to characterize the surface of particles. This parameter 
defines the electrical potential of particles and depends on the composition, the pH medium and 
other factors in which NPs or liposomes are dispersed [13, 14].  
Our zeta potential results show negative values for PLGA-PVA NPs and neutral values for 
PLGA-PVA-E1P47 NPs (table 2). PLGA NPs, as reported in many studies, have a negative 
charge that can be attributed to the presence of end carboxyl groups of the polymer on the 
nanoparticle surface [15]. However, there are some studies that tested PVA coating of PLGA 
NPs and found exhibited neutral zeta potential or decrease its negative charge [15]. The mucus 
layer itself is at a neutral pH value an anionic polyelectrolyte. The neutrality of PLGA-PVA-
E1P47 NPs shown in table 1 should minimize particle electrostatic/ionic interactions with mucus.  
LUVs are composed by the zwitterionic lipid POPC, meaning it has a neutral charge 
surface. Even though zeta potential is -13±1 for POPC LUVs, as shown in table 2, some studies 
have previously reported that some neutral liposomes exhibit non-zero zeta potential in an 
electric field even when they are dispersed at pH 7.4 due to the orientation of lipid head groups 
in the liposome surface. The direction of the lipid head group depends on temperature and ionic 
strength [13]. According to this study, the phosphatidyl groups are located at the outer portion of 
the head group region and choline groups hide behind the surface.  
Zeta potential can also indicate if charged material is found adsorbed onto the surface of 
NPs. In one hand, in table 2 shows the increase in zeta potential of PLGA-PVA E1P47 NPs with 
respect to PLGA-PVA NPs, could be attributed to part of the peptide has not been encapsulated 
and is found on the surface of the nanoparticles varying its zeta potential. On the other hand, 
zeta potential measurement of E1P47 (table 2) revealed that the positive charge has influenced 
to surface of POPC LUVs decreasing their negativity until obtaining a zeta potential of -3.5 ± .1 
for POPC LUVs E1P47. This fact could be attributed that part of E1P47 could be entrapment 
between lipidic bilayers. 
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Formulation Zpot ± SD (mV) 
Free E1P47 10.6 ± 0.6 
PLGA-PVA NPs  -13 ± 1 
PLGA-PVA-E1P47 NPs Neutral  
POPC LUVs -13 ± 1 
POPC LUVs E1P47 -3.5 ± 0.1 
Table 2. Zeta potencial values E1P47, PLGA-PVA NPs, PLGA-PVA-E1P47 NPs, POPC LUVs and POPC 
LUVs E1P47 (n=30).  
According to the results obtained from particle stability studies (table 3 and 4), nanoparticles 
and liposomes sizes and PdI remained stable for almost a month and a half at 4ºC. Although in 
the later measure slight increase in particle size can be observed. 
 
Day Size ± SD (nm) PdI ± SD 
0 245 ± 2 0.094 ± 0.004 
4 240 ± 2 0.07 ± 0.05 
12 242 ± 3 0.09 ± 0.01 
40 250 ± 10 0.11 ± 0.01 
Table 3. Size and PdI values for PLGA-PVA E1P47 NPs samples at different days (n=30) 
 
Day Size ± SD (nm) PdI ± SD 
0 95 ± 2 0.07  ± 0.02 
4 100 ± 1 0.09 ± 0.03 
8 100.1 ± 0.8 0.12 ± 0.02 
16 97 ± 1 0.08 ± 0.01 
44 107 ± 3. 0.10 ± 0.04 
Table 4. Size and PdI values for POPC LUVs samples at different days (n=30). 
To calculate the amount of the E1P47 peptide loaded in LUVs and NPs the entrapment 
efficiency was assessed indirectly, determining the free E1P47 (non-encapsulated) by HPLC 
analytical method using a standard curve of E1P47 and applying the equation 1. The standard 
covered a range from 4 µg/mL to 63 µg/mL and included a total of eight standards 
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concentrations. The standards, LUVs E1P47 and NPs E1P47 were analysed by analytical 
reversed -phase HPLC as explained before. 
The linearity study verified that the sample solutions were in a concentration range where 
analyte response was proportional to the concentration. Linearity was established by calculation 
of a regression line from the graphical plot of the chromatographic peak area versus E1P47 
standard concentration obtaining a calibration curve. Linearity was studied by calculating the 
regression equation and the correlation coefficient (r2) of the calibration curve. The calibration 
curve and correlation coefficient were y= 31990.2 x - 5.6 and 0.9998 respectively. The 
correlation curve is shown below in figure 10.  
 
 
 
 
 
 
Figure 10. Linear regression from the standard curve generated with E1P47. 
The E1P47 content of NPs and LUVs are listed in the table 5. The E1P47 content of the 
POPC LUVs E1P47 was 93%, larger than PLGA-PVA E1P47 NPs.   
 
Formulation EE (%) 
PLGA-PVA E1P47 NPs  69% 
POPC LUVs E1P47 93% 
Table 5. PLGA-PVA E1P47 NPs, POPC LUVs E1P47 entrapment efficiency. 
 
 
 
 
 
y = 31990.2x – 5.6 
r² = 0.9998 
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6.2 OPTIMIZATION OF UPLC-MS/MS FOR E1P47 QUANTIFICATION 
Two standards curves were made using E1P47 in transcutol®/H2O 1:1 (v/v) and other using 
ACN/H2O 1:1 (v/v) to evaluate the concentrations of all samples in ex vivo and in vitro. The two 
curves contained fifteen standards of E1P47 from 0.02 µg/mL to 350 µg/mL.  
This experiment used the selectivity of the triple quadrupole mass spectrometer by only allowing 
ions with specific mass, that of the intact peptide or parent ion, to be transmitted to the triple 
quadrupole detector (TQD) in the collision cell. The intact peptide ions are fragmented in the 
collision cell producing daughter ions. In a Multiple reaction monitoring (MRM) experiment, more 
than one daughter is transmitted to the third quadrupole. The mass spectra of E1P47 were 
acquired under a positive ESI at 0.3 mL/min flow rate. The average mass spectra of E1P47 are 
shown in figure 11. The mass spectrum of E1P47 shows a base peak at m/z 1184.3 and low-
abundant peak at m/z 790.3, corresponding to the triply and doubly charged molecular ions of 
E1P47, respectively.  
As shown in figure 11 the doubly charge ions of E1P47 (m/z 1184) were selected for the 
collision-induced dissociation (CID), since they were the most abundant ions. The cone voltage 
was optimized at 50 V to obtain the most intense sight for the peak.      
Figure 11. The average mass spectra from E1P47 under ESI at 50 V of cone voltage. 
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The CID spectrum of E1P47 (figure 12) shows two abundants peaks at 159 m/z and 272 
m/z. Therefore, the precursor/parents ion was at m/z 1184/159-279 were selected in the MRM 
mode for quantification of E1P47. The collission energy was optimizated at 60 V. 
Figure 12. The CID mass spectra of doubly charged molecular ion of E1P47 at m/z 1184 with 60 V of 
collission energy showing 159 m/z and 279 m/z peaks 
All standard were analyzed with the optimized parameters and  using the conditions 
explained before. The obtained curve standards for E1P47 in transcutol®/H2O 1:1 (v/v) and for 
ACN/H2O 1:1 (v/v) were not lineal, as shown in figure 13a and figure 14a. Due to the two curves 
having polynomial distribution, they have been segmented in different sections, one for each 
rang, obtaining three linear regression for curve standards of E1P47 in transcutol®/H2O 1:1 (v/v), 
(figure 13b, 13c and 13d) and two for E1P47 in ACN/H2O 1:1 (v/v) (figure 14b, 14c and 14d). 
 
 
 
 
 
 
 
Biopharmaceutic study of an HIV-1 inhibitor peptide using nanosystems.   29 
 
 
Figure 13. a) Polynominal regression from standard curve generated using E1P47 in Transcutol®/H2O 1:1 
(v/v). b) Liniar regression from 0.02 – 0.34 µg/mL of E1P47. c) Liniar regression from  0.34 – 2.73 µg/mL 
of E1P47. d) Liniar regression from 2.73 – 43.75 µg/mL E1P47 
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Figure14. a) Polynominal resgression from standard curve generated using ACN/H2O 1:1 (v/v). b) 
Liniar regression from 0.03 – 0.98 µg/mL of E1P47. c) Liniar regression from 0.98 – 7.81 µg/mL of E1P47. 
6.4 IN VITRO RELEASE AND STABILITY OF FREE E1P47 STUDIES 
Release studies are mandatory to evaluate the efficacy of drug delivery of the two 
nanosytems (NPs and LUVs) with E1P47 that are developed in this study, and also for free 
E1P47.  
In vitro release profiles of the three preparations were fitted to a monocompartmental model 
using WinNonlin v5.2. This profile corresponds to pharmacokinetic model, where two steps 
peptide entry and elimination occurs simultaneously. In our case, the peptide elimination could 
be attributed to possible peptide degradation in receptor medium. On the other hand, to carry 
out the release study 0.4 mL of each sample were added to the dialysis membrane. At the end 
of the study no liquid onto dialysis membranes was observed, indicating that the whole volume 
crossed the dialysis membrane, thus diluting the receptor phase. Finally, observing the 
elimination step on the release profile. 
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Figure 15 illustrates the different monocompartmental model parameters which are entry 
rate constant (Ka), elimination rate constant (K10), maximal drug level contained (Cmax), time at 
which Cmax occurs (Tmax) and time from to administration appear on medium (Ltme). 
 
 
 
 
 
Figure 15. Monocompartmental model 
Next, the observed release profile and the one set to a monocompartmental model are 
shown of the samples tested in the release assay. 
Free E1P47 monocompartmental model and the observed release profile are show in figure 
16 and table 6 respectively. The entry rate constant is (1.9 ± 0.3) 10-1 h-1 (Ka) and the 
elimination rate constant is (6 ± 3) · 10-2 h-1 (K10). The entry of peptide starts at 1 ± 1 · 10-1 hours 
(Ltime) and reaches maximum concentration of E1P47 is at 11 ± 2 hours (Tmax) from this moment 
the amount of peptide begins to decrease.  
Figure 16. Duplicate in vitro release profile, monocompartmental fitted model of free E1P47 expressed 
by mean and standard deviation. 
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 Ka (h-1) K10 (h-1) Ltime (h) Qmax (µg) Tmax (h) 
E1P47 (a) 1.50 · 10-1 9.4 · 10-2 1.3 2.1 9.6 
E1P47 (a’) 2.31 · 10-1 2.5 · 10-2 1.5 1.5 12.6 
Mean ± SD (1.9 ± 0.3) 10-1 (6 ± 3) · 10-2  1 ± 1 · 10-1 2 ± 3 ·10-1 11 ±  2  
Table 6. Pharmacokinetis parameters from free E1P47 release expressed by mean and standard 
deviation (n=2). 
Figure 17 shows the release profiles of E1P47 from NPs and the pharmacokinetic 
parameters in table 7. As it can be observed, the entry constant (Ka) is quite pronounced and 
the elimination constant is (2.8 ± 0.3) · 10-2 h-1 (K10). The maximal drug contained (Qmax) is seen 
at 8 ± 1 hours and from this point the amount begins to decrease. The release of drug depends 
upon the nature of delivery system, in our case, peptide is uniformally distributed or dissolved in 
the matrix and the release occurs by diffusion or erosion of the matrix. Rapid initial release is to 
burst effect, attributed to the fraction of the drug which is adsorbed or weakly bound to the large 
surface area. of the NPs. 
Figure 17. Duplicate in vitro release profile and monocompartmental model fitted of PLGA-PVA-E1P47 
NPs expressed by mean and standard deviation. 
 
 Ka (h-1) K10 (h-1) Ltime (h) Qmax (µg) Tmax (h) 
PLGA-PVA-E1P47 NPs (b) 6.59 ·10-1 3.03 · 10-2 2.9 4.1 9.4 
PLGA-PVA-E1P47 NPs (b’) 5.41 · 10-1 2.50 · 10-2 0.8 11.8 7.5 
Mean ± SD (6.0 ± 0.6)· 10-1 (2.8 ± 0.3) · 10-2 2 ± 1 8 ± 4 8 ± 1  
Table 7. Pharmacokinetis parameters from PLGA PEG E1P47 NPs release (n=2).  
Monocompartmental fitted and observed proflie from POPC LUVs E1P47 are shown below 
(figure 18 and table 8). It can be observed that the release profile is sustained over time with a 
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rate entry constant of  (1.1 ± 0.3) ·10-1 h-1. The maximal E1P47 release level is at 23 ± 1 hours 
and lag time is at 3 ± 2 hours. These results describe a slow release of the peptide, which could 
be due to the peptide being trapped between the lipid bilayer. 
Figure 18. Duplicate in vitro release profile and monocompartmental model fitted of POPC LUVs 
E1P47 expressed by mean and standard deviation. 
 
 Ka (h-1) K10 (h-1) Ltime(h) Qmax (µg) Tmax (h) 
POPC LUVs E1P47 (c) 1.42 · 10-1 1.81·10-2 4.7 1.6 24.2 
POPC LUVs E1P47 (c’) 7.72 ·10-2 9.21 ·10-3 7.48 · 10-1  1.4 21.8 
Mean ± SD (1.1 ± 0.3) ·10-1 (1.4 ± 0.4) · 10-2 3 ± 2 1.5 ± 7· 10-2 23 ± 1 
Table 8. Pharmacokinetis parameters from POPC LUVs E1P47 release (n=2). 
In all three preparations, the release assay was performed in duplicate. Some parameters 
showed significant differences between them, such as the lag time in PLGA-PVA-E1P47 NPs 
(table 7) release or in POPC LUVs E1P47 (table 8) release. This could be due to the difficulty of 
quantifying the peptide found in the medium at such low concentrations. 
The release profiles obtained for the free peptide and the NPs formulations were very 
similar, showing a rather pronounced release profile, somewhat greater in the case of the 
release of the peptide in the nanoparticles. In contrast, the loaded peptide in the liposomes 
showed slower release. 
As explained before, 0.4 mL of each sample were added in duplicate at a 0.350 mg/mL, 
0.379 mg/mL and 0.376 mg/mL concentration of free E1P47, POPC LUVs E1P47 and PLGA-
PVA E1P47 NPs respectively. Thus, the amount of peptide used for each sample was 140.0 µg 
for free peptide, 150 for PLGA-PVA-E1P47 NPs and 151.6 µg for POPC LUVs E1P47. The 
maximal amount of peptide found in the medium (Qmax) was 1.8 ± 3 ·10-1 µg (table 6), 8 ± 4 µg 
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(table 7) and 1.5 ± 7· 10-2 µg (table 8) respectively for each preparation. This represents a very 
small amount of peptide founded in the receptor phase. Thus, a peptide extraction of each 
membranes was carried out to quantify the peptide that might have been retained in them.  
Table 9 shows the retained peptide on each release membrane. The amount of entrapped 
peptide in the membrane remains very low in all cases. 
 
Formulation Peptide retained in the 
membrane (µg) 
Free E1P47 (a) 1.07 
Free E1P47 (a’) 0.00 
PLGA-PVA-E1P47 NPs (b) 1.17 
PLGA-PVA-E1P47 NPs (b’) 4.14 
POPC LUVs E1P47 (c) 2.03 
POPC LUVs E1P47 (c’) 1.06 
Table 9. Quantity of peptide retained in the release membranes.  
Due to the low recovery rate of the peptide in the medium and the membrane, it was 
hypothesized that the peptide could have undergone a degradation process. 
To corroborate the hypothesis of a possible degradation of the peptide in the receptor 
medium and low recovery rate of the peptide, a stability study of the peptide was performed in 
the same medium and temperature that study in vitro, which was in transcutol®/H2O 1:1 (v/v) 
and 37ºC respectively for 48 hours. Peptide solution had a concentration of 0.072 mg/mL.   
The samples and the standard curve of E1P47 were analysed with the following optimized 
parameters: the precursor/parents ion was at m/z 790/159-279 were selected in the MRM 
mode, the cone voltage was optimized at 20 V and  collission energy  of 159 m/z and 279 m/z 
peaks was 60 V and 30 V respectivly. The obtained standars curve of E1P47 in transcutol®/H2O 
1:1 (v/v) is shown at below at figure 19. 
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Figure 19. Lineal resgression from 0.018 to 72.00 µg/mL of E1P47 standard curve generated using 
transcutol®/H2O 1:1 (v/v). 
Figure 20 illustrates the results of the study and shows that peptide concentration decreases 
17 % in a period of 2 days. The profile was fitted to exponential curve.  
E1P47 shows a slight degradation. Another plausible reason for decrease E1P47 
concentration would be possible to peptide aggregation due to the peptides hydrophobicity. 
Aggregation depends on several factors such as ionic strength, pH or peptide concentration. In 
this case, the addition in the receptor compartment was 5 times more concentrated than in the 
stability study, so a possible aggregation could have happened. More aggregation studies 
should be carried out at study concentration. 
Figure 20. Degradation of E1P47 at 37ºC in transcutol®/H2O 1:1 (v/v) for 48 hours. 
6.4 IN VITRO PERMEATION STUDY 
To develop the permeation experiment, 0.4 mL of each sample were added in duplicate at a 
0.35 mg/mL, 0.39 mg/mL and 0.34 mg/mL concentration of free E1P47, POPC LUVs E1P47 
and PLGA-PVA-E1P47 NPs respectively to the donor compartment. Thus, the amount of 
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peptide used for each sample was 140.0 µg for free peptide, 136.0 for PLGA-PVA-E1P47 NPs 
and 156.0 µg for POPC LUVs E1P47.  
All samples were analysed by HPLC. In all receptor medium, none E1P47 peptide was 
found. Given this result, it can be considered that the whole amount of added peptide was 
retained in the mucosa.  
First, the determination of the peptide retained in the mucosa was necessary to evaluate the 
recovery. Recovery was calculated applying the equation 2 described in ex vivo permeation 
study from the experimental section. In the assay 41 μg/mL (Co) was added to each mucosa. All 
values can be observed in the table 9.  
 
Mucosa Wt (g) Wt’ (g) Ctrans (µg/mL) Cacn (µg/mL) Recovery (%) 
1 0.63130 0.53982 21.05 4.50 22 
2 0.39300 0.29994 22.15 3.60 21 
3 0.53416 0.40343 23.20 4.65 28 
Table 9. Recovery results expressed by percent (n=3). 
Mean and standard deviations for recovery values was 24 ± 3 %. 
The quantity of peptide retained in the mucosa was calculated applying equation 3. The 
concentration of peptide extracted from the mucosa (Cp), weight of the mucosa (Wp) and the 
actual quantity of peptide are shown in table 10.  
 
Formulation Cp (µg/mL) Wp (g) Quantity of 
peptide retained 
(µg/g · cm-2) 
Medium ± SD 
(µg/g · cm-2) 
Free E1P47 (a) 0.23 0.50 3.03 10 ± 7  
Free E1P47 (a’) 1.05 0.39 17.75 
PLGA-PVA-E1P47 NPs (b) 0.27 0.51 3.49 3.6 ± 0.1 
PLGA-PVA-E1P47 NPs (b’) 0.16 0.29 3.64 
POPC LUVs E1P47 (c) 2.65 0.36 48.53 40 ± 8 
POPC LUVs E1P47 (c’) 2.33 0.48 32.00  
Table 10. Values of Cp, WP and quantity of peptide retained of free E1P47, PLGA-PVA-E1P47 NPs and 
POPC LUVs E1P47 (n=2). 
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The most important question is whether this concentration of peptide found inside the 
mucosa would be sufficient to inhibit the entry of the virus to cell membrane. There is an ex vivo 
study performed with T-20, an HIV-1 inhibitory peptide, which have shown a significant inhibition 
of viral genomic integration in intraepithelial vaginal cells with a IC50 of 0.153 μM [16]. This value 
can give an idea of the order of concentration of peptide that is needed to inhibit a HIV-1. 
In our case, the inhibition of replication of HIV-1 NL4-3 in cell cultures E1P47 showed a 
strong inhibitory activity, IC50 3 μM [9]. As shown in table 11, of all developed formulation only 
POPC LUVs E1P47 showed a concentration greater than IC50. Therefore, LUVs can be 
considered the best candidate to act as a possible microbicide with a concentration of 11 ± 2 
µM. 
 
Formulation Concentration 
of peptide 
retained (µM) 
Mean ± SD 
(µM) 
Free E1P47 (a) 0.81 3 ± 2 
Free E1P47 (a’) 4.73 
PLGA-PVA-E1P47 NPs (b) 0.93 0.95 ± 0.02 
PLGA-PVA-E1P47 NPs (b’) 0.97 
POPC LUVs E1P47 (c) 12.95 11 ± 2 
POPC LUVs E1P47 (c’) 8.54  
Table 11. Values of concentration of peptide retained of free E1P47, PLGA-PVA-E1P47 NPs and POPC 
LUVs E1P47 (n=2). 
However, an ex vivo study of microbicide efficacies for preventing HIV-1 genomic integration 
in intraepithelial vaginal cells should be carried out to confirm that these results are accurate.  
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7. CONCLUSIONS 
PLGA-PVA-E1P47 and POPC LUVs E1P47 were correctly prepared. The two formulations 
showed a suitable mean size for the permeation through the vaginal mucosa (less than 500 nm) 
and polydispersity index (PdI) of less than 0.1 corresponding to monodisperse system. High 
encapsulation efficiency was observed. 
Stability studies performed at 4 ° C of both formulations revealed that the particle size was 
constant but with a slight increase after a month and a half of their storage. The polydispersion 
was constant throughout the experiment with its value very close to 0.1. 
The stability study of the peptide mimicking the conditions of the in vitro and ex vivo studies 
showed a degradation of 17% in 48 hours. 
The formulation of PLGA-PVA-E1P47 did not slow down the release of E1P47, showing a 
very similar release profile to the free E1P47. The concentration of E1P47 retained in the 
vaginal mucosa of both preparation was lower than active concentration (IC50 = 3µM), which has 
been reported in other studies, showing that PLGA-PVA-E1P47 and free E1P47 are not an 
adequate choice to be a microbicide.  
The developed formulation of LUVs showed a sustained release of E1P47. The 
concentration of E1P47 retained in the vaginal mucosa was also greater than IC50, suggesting 
that this formulation could be a suitable candidate as a potential microbicide. 
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9. ACRONYMS 
ACN     Acetonitrile 
AIDS     Acquired immunodeficiency syndrome 
CAPRISA     Centre for AIDS Program of Research in South 
     Africa 
CDI     Collision- induced dissociation  
DPV     Dapivirine 
DCs     Dendritic cells 
DNA     Deoxyribonucleic acid 
DMSO    Dimethyl sulfoxide 
EE     Entrapment efficiency 
FA     Formic acid 
GBV-C    GB virus C 
Fmoc/tBu    9-fluorenylmethoxycarbonyl/tet-butyl 
FP     Fusion peptide 
FTMLV    Freeze and thaw multilamellar vesicles 
HIV-1    Human immunodeficiency virus type 1 
HIV-2    Human immunodeficiency virus type 2 
HPLC    High-performance liquid chromatography 
LCs     Langerhan cells 
LUVs     Large unilamelar vesicles 
MLV     Multilamellar vesicles 
MRM     Multiple reaction monitoring 
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MW      Molecular weight 
NPs     Nanoparticle 
NNRTIs    Non-nucleoside transcriptase inhibitors 
NRTIs    Nucleoside transcriptase inhibitors 
LUVs     Large unillamelar vesicles  
PdI     Polidispersity index 
PC     phosphocholine 
PLGA    Poly(D,L-lactide-co-glycolide) 
POPC 1-Palmitoyl-2-oleoyl-sn-glycero-3-
posphocholine 
PVA     Polivynilic alcohol 
RNA     Ribonucleic acid 
SD     Standard deviation 
SPPS    Solid phase peptide synthesis 
SUV     Small unillamelar vesicles 
TFV     Tenefovir 
UPLC-MS/MS    Ultra-performance liquid chromatography- 
     tandem mass spectrometry  
USP      The United States Pharmacopeia 
VOICE    Vaginal and Oral Interventions to Control the 
     Epidemic 
Zpot     Zeta potential 
 
   
  
